Kimia Biosciences Limited

KIMIABL

INE285U01025

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 11:00:58 28/06/2024 BST			5-day change	1st Jan Change
52.46 ^INR	+0.90%		+0.81%	+42.55%

06-14	Kimia Biosciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI
06-14	Kimia Biosciences Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI

Kimia Biosciences Limited Bags Permission to Manufacture Bilastine API New Active Pharmaceutical Ingredient for Sale or for Distribution

March 16, 2021 at 06:15 am

Kimia Biosciences Limited announced that the Company has been granted' permission to manufacture new API for sale or for distribution' namely Bilastine by Central Drugs Standard Conirol Organization, Ministry of Health & Family Welfare, FDA Bhawan, New Delhi -110002 (India) Vide permission No. MF/SND/2I/OOOOTZ in FORM cr-22 under Drugs & cosmetics Acts & Rules thereunder.

Latest news about Kimia Biosciences Limited

Kimia Biosciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	06-14	CI
Kimia Biosciences Limited Reports Earnings Results for the Full Year Ended March 31, 2024	06-14	CI
Kimia Biosciences Limited Announces Resignation of Mita Namonath Jha as Non- Executive, Non- Independent Director	04-01	CI
Kimia Biosciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-14	CI
Kimia Biosciences Limited Appoints Mita Namonath Jha as an Non Executive, Non Independent Director of the Company	03/10/23	CI
Kimia Biosciences Names CFO	07/09/23	MT
Kimia Biosciences Limited Announces Chief Financial Officer Changes	07/09/23	CI
Kimia Biosciences Limited Announces Appointment of Ms. Mita Namonath Jha as an Additional Director (Non-Executive and Non-Independent Director )	28/08/23	CI
Kimia Biosciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	14/08/23	CI
Kimia Biosciences Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	01/06/23	CI
Kimia Biosciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	01/06/23	CI
Kimia Biosciences Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	01/06/23	CI
Kimia Biosciences Names New CFO	13/02/23	MT
Kimia Biosciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	14/11/22	CI
Arti Resigns as Chief Financial Officer of Kimia Biosciences Limited	12/08/22	CI
Kimia Biosciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	12/08/22	CI
Kimia Biosciences CEO Resigns	31/05/22	MT
Kimia Biosciences Limited Appoints Sameer Goel as Chief Executive Officer	30/05/22	CI
Kimia Biosciences Limited Announces Resignation of Suneel Kapoor as Chief Executive Officer	23/05/22	CI
Kimia Biosciences Gets Nod to Manufacture Bemopedoic Acid Bulk drug.	18/05/22	MT
Kimia Biosciences Limited Announces Granted Permission to Manufacture and Marketing of Bemopedoic Acid Bulk Drug Under New Drug and Clincial Trials	17/05/22	CI
Kimia Biosciences Limited Announces Appointment of Lakshay Prakash as Company Secretary	16/05/22	CI
Kimia Biosciences Names New CFO	29/04/22	MT
Kimia Biosciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	14/02/22	CI
Kimia Biosciences Gets Regulatory Nod to Supply Pharmaceutical Raw Material to Bangladesh	30/12/21	MT

Chart Kimia Biosciences Limited

Duration

Period

More charts

Company Profile

Kimia Biosciences Limited is an India-based company, which is engaged in the business of pharmaceutical products. The Company provides its products under various categories: Commercial Active Pharmaceutical Ingredients (APIs), Commercial KSMs, Intermediates & Reagents. The Company's Commercial-APIs products include acotiamide hydrochloride hydrate, azelnidipine, benfotiamine, benidipine hydrochloride, citicoline sodium, gliclazide, dapagliflozin propanediol monohydrate, levosulpiride, luliconazole, oxaceprol, prucalopride succinate, teneligliptin hydrobromide hydrate, vildagliptin, fimasartan trihydrate potassium, obeticholic acid and ursodeoxycholic acid. Its Commercial KSMs, Intermediates & Reagents products include Ethyl-2-Amino 1,3-Thiazole 4-Carboxylate, 2,4,5-Trimethoxy Benzoic Acid, Ethyl 2-(2,4,5-trimethoxybenzamido)-1,3-thiazole-4-carboxylate, Isopropyl 2-(3-Nitrobenzylidene) Acetoacetate, Choline phosphate chloride calcium, and more.

Sector

Pharmaceuticals

Calendar

11/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
KIMIA BIOSCIENCES LIMITED	+42.55%	29.77M
ELI LILLY AND COMPANY	+55.32%	815B
NOVO NORDISK A/S	+44.05%	641B
JOHNSON & JOHNSON	-6.75%	352B
MERCK & CO., INC.	+13.56%	314B
ABBVIE INC.	+10.68%	303B
ASTRAZENECA PLC	+16.57%	242B
ROCHE HOLDING AG	+2.04%	224B
NOVARTIS AG	+13.31%	218B
AMGEN INC.	+8.48%	168B